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Exosomes are nano-vesicles (NVs) secreted by cells and take part in cell-cell communications. Lately, these
exosomes were proved to have dual faces in cancer. Actually, they can contribute to carcinogenesis through
epithelial-mesenchymal transition (EMT), angiogenesis, metastasis and tumor microenvironment (TME) of
various cancers, including colorectal cancer (CRC). On the other hand, they can be potential targets for cancer
treatment. CRC is one of the most frequent tumors worldwide, with incidence rates rising in the recent decades.
In its early stage, CRC is asymptomatic with poor treatment outcomes. Therefore, finding a non-invasive, early
diagnostic biomarker tool and/or suitable defender to combat CRC is mandatory. Exosomes provide enrichment
and safe setting for their cargos non-coding RNAs (ncRNAs) and proteins, whose expression levels can be
upregulated ordown-regulated in cancer. Hence, exosomes can be used as diagnostic and/or prognostic tools for
cancer. Moreover, exosomes can provide a novel potential therapeutic modality for tumors via loading with
specific chemotherapeutic agents, with the advantage of possible tumor targeting. In this review, we will try to
collect and address recent studies concerned with exosomes and their cargos’ implications for CRC diagnosis
and/or hopefully, treatment.

1. Introduction

[17]. One of the important components of the exosomes cargo that were
found to be implicated in cancer is exosomal lncRNAs.

1.1. Colorectal cancer (CRC)

1.3. Long non-coding RNAs (lncRNAs)

1.1.1. Colorectal Cancer (CRC) statistics
In the past few years, colorectal cancer (CRC) became one of the
highest prevalent cancers worldwide to the extent that it is recorded the
3rd most diagnosed cancer and the 2nd major cause of cancer related
death all over the world [1]. In Egypt, it is rated the 7th most common
malignancy, representing 3.5% of male cancer cases and 3% of female
cancer cases [2]. CRC is a complex malignancy with a noteworthy
number of standard well recognized risk factors including old age, male
gender, family history, inflammatory bowel disease (IBD) syndrome,
obesity and overweight, excessive alcohol intake, smoking, sedentary
lifestyle, diabetes and high ingestion of red and processed meat [3,4].
Additionally, chronic intestinal inflammation in patients with IBD is
considered a chief risk factor for CRC development. Also, patients
suffering from Crohn’s disease or ulcerative colitis, show an increased
risk rates towards CRC that account for 10% of all mortality in those IBD
patients [5].

These lncRNAs are a class of RNAs (more than 200 nucleotides in
length) without protein-coding capability [18], Historically, lncRNAs
were considered as transcriptional noise, however, recent studies showed
that lncRNAs can serve important roles in several biological processesregulations [19], including gene regulation at transcriptional or posttranscriptional level, chromatin dynamics and genomic imprinting
[20]. LncRNAs can control gene expression via lncRNA-miRNAs in
teractions, lncRNA-mRNA interactions and lncRNA-target protein in
teractions [21]. Several studies proved some lncRNAs have vital roles in
tumorigenesis process via regulating either the tumor suppressor genes
or the proto-oncogenes, affecting the main metabolic enzyme(s) and
mRNAs [22].
In an attempt, to improve our understanding of the role of exosomal
lncRNAs, as cancer key players in CRC-pathogenesis, we decided to
undertake this review.

1.1.2. Problem Statement Definition
CRC in its early stage is often asymptomatic. Once symptoms start to
appear, rapid diagnosis becomes really crucial, since any delay in
diagnosis may lead to higher mortality rates [6]. Nowadays, chemo
therapy, radiotherapy and surgery are the main CRC treatment strate
gies. However, recurrence and metastasis are common to occur after
CRC treatment or surgical removal. This explains the scary numbers of
mortalities associated with CRC, and how it represents a huge risk to
human health [7]. Lately, an interesting key player in tumor develop
ment and intercellular communication; especially in CRC; are exosomes
[8].

1.4. Review search methodology
An online search during the period from January to April, 2021, for
published research articles and various types of reviews, in English
language, within the past 10 years, in the e-medical databases; Science
Direct and PubMed databases by using these key words (Colorectal
Cancer) OR “CRC” AND (long-non-coding RNAs’) OR “lncRNAs’” AND
“exosomes’” AND (exosomal-lncRNAs’) AND (hallmarks’ of colorectal
cancer).
1.5. Review aim
In the current narrative review, we will address the role of exosomal
lncRNAs in diagnosis, prognosis and as potential therapeutic targets for
CRC. First, we will summarize the role of exosomes and lncRNA in
cancer generally and then in CRC specifically, discussing interactions of
these exosomal lncRNAs with different pathways and hallmarks of CRC.
Then, we will discuss the role of exosomes and lncRNA as potential
diagnostic/prognostic marker(s) and as potential therapautic target of
CRC pathogenesis.

1.2. Exosomes
Exosomes are nano-sized extracellular vesicles (30–150 nm), pro
duced endogenously by, nearly, all cell types. Exosomes can contribute
in intercellular communication, through delivering messenger RNA
(mRNA), ncRNAs; including micro RNAs (miRNA) or long non-coding
RNA (lncRNA); and proteins to recipient cells [9]. Interestingly, it was
found that exosomal secretion by cancer cells is more than that from
normal cells [10]. Furthermore, exosomes are involved in several
important processes in cancer development, including metastasis and
the TME as well as multi-drug-resistance (MDR) [11].
Interesrtingly, exosomes, through their cargos, were found to play
crucial roles in several aspects of CRC including initiation, promotion of
anti-apoptotic signaling pathways [12], enhancing tumorigenicity [13],
proliferation of CRC cancer stem cells [14], induction of angiogenesis
[15], immunosuppressive environment establishment [16], endothelial
cell migration, as well as creation of pre-metastatic niche and metastasis

2. Exosomes and LncRNAs
2.1. Exosomes; the extracellular nano-vesicles
2.1.1. Extracellular vesicles
The International Society for Extracellular Vesicles (ISEV) supports
the term "extracellular vesicle" (EV) as a generic name for particles that
are spontaneously released from the cell, which are delimited by a lipid
2
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nucleus or endoplasmic reticulum after contact of the nucleus’ or
endoplasmic reticulum’s membrane with endosomes containing
internalised exosomes [39,40]. As shown in Fig. 1, generation of exo
somes occur in a constitutive manner from the late endosomes formed
by inward budding of the MVB membrane. The late endosomal mem
branes then invaginate to form intraluminal vesicles (ILVs) inside these
large MVBs. Throughout this process, specific proteins and cytosolic
components are integrated within these ILVs [30]. Afterward, MVBs fuse
with the cellular plasma membrane and expel its ILVs into the extra
cellular space in the form of exosomes [41]. ILVs creation needs the
endosomal sorting complex required for transport (ESCRT); a complex
composed of four distinct proteins (ESCRT 0, I, II and III) that works in
co-operation to assist MVB construction, vesicular budding, and sorting
different “exosomal cargos” [42].

bilayer, and cannot multiply, i.e. do not include a functioning nucleus
[23]. The study of secreted membrane vesicles, also known as EVs, has
exploded in popularity over the last decade. EVs have been considered as
having fascinating functional roles in high-impact publications. The
discovery that EVs may transport functional nucleic acids between cells
(mRNA, miRNA, and other RNA species) has fundamentally altered how
we think about gene regulation, because EVs can govern the recipient
cell at the post-transcriptional level. Previously, the term “exosomes”
has been the most commonly used word to designate any type of EVs,
and this has become a “buzz term” for EV-related science. However, over
the past decade, there has been a growing body of evidence for various
distinct types of secreted membrane vesicles, collectively called extra
cellular vesicles (EVs). [24]. Table 1 summarizes the difference between
various prominent types of EVs, namely, exosomes, microvesicles and
apoptotic bodies.
It is noteworthy here to differentiate exosomes from microvesicles
(MVs) and apoptotic bodies (ABs) as shown in Table 1. MVs are
100–1000 nm in size membrane vesicles with different shapes. Unlike
the exosomes, MVs are formed by outward budding of the plasma
membrane (PM). They are characterized as products of endothelial cells,
red blood cells and platelets [25]. On the other hand, ABs range in size
from 50 to 5000 nm, exclusively generated from the PM during
apoptosis late phases [26]. ABs enclose many cellular organelles,
intracellular fragments and cytosolic components [27]. Interestingly,
the relatively smaller size and regular shape characterizing exosomes,
allow them to succeed in escaping the phagocytic system clearance,
resulting in prolongation of their circulation time, in-favor of their role
as intercellular communicators [28].

2.1.3. Isolation techniques of exosomes
Different biophysical and biochemical properties could be taken into
consideration to isolate exosomes such as particle size, density, shape,
charge and exposed surface proteins [43]. However, the isolation tech
nique would have an impact on the obtained exosomes concentration,
some techniques could be used alone to concentrate them and others
could be combined together [44]. These isolation methods include the
ultracentrifugation that comprises two major types: differential ultra
centrifugation (in which different particles are separated by the use of a
sequence of different centrifugal forces and time intervals) and density
gradient ultracentrifugation (in which exosomes are isolated by sucrosegradient centrifugation) [45]. Another method comes to overcome the
time consuming and the requirement of specific separation equipment
by the ultracentrifugation technique which is filtration that depends on
the molecular weight and the particle size of exosomes isolated [46]. Coprecipitation technique, in which polymers could be used to coprecipitate hydrophobic proteins and lipid molecules. Lately, a num
ber of commercial kits (e.g., Exo-Spin, Total Exosome Isolation, Exo
Quick) use co-precipitation methodology to concentrate and purify
these small EVs, however, the relatively little throughput and contam
ination with chemicals can somehow limit its use [47]. An
immunoaffinity-capture-based approach for exosomal extraction was
established based on loading the micro-channel surfaces employed with
particular antibodies to the exosomal specific proteins incorporated in
its phospholipid bilayer as CD9, CD63, and CD81 [43]. These different
techniques are summarised in Fig. 2.

2.1.2. Exosomes biogenesis
Exosomes are extracellular phospholipid bilayer vesicles originated
from nearly all types of mammalian cells and are required for commu
nication between cells [34]. Various proteins and lipids originated from
the exosomal-parent cells are embedded within the exosomal phos
pholipid bilayer. Therefore, exosomes are distinctive to the mother cellof-origin [35]. Basically, exosomes released from tumor cells use such
intercellular communication to aid tumor propagation and metastasis
[36]. Currently, there is lack of consensus regarding the exosomal
markers [23]. However, several proteins have been repeatedly reported
to be detected in exosomes such as cluster of differentiation (CD) CD63,
CD81, CD9 tetraspanins, proteins responsible for exosomal transfer and
binding to their target cells such as GTPases, annexins, flotillin, heat
shock proteins (HSPs) such as HSP70, HSP90 and the proteins required
for the biogenesis of multivesicular bodies (MVB) like apoptosis-linked
gene-2 interacting protein X (ALIX), and tumor susceptibility gene
(TSG)101 [37]. These nano-vesicles encompass various RNA molecules
such as mRNAs,miRNAs and lncRNAs [29]. These various RNAs serve as
cargos circulating within the body fluids, that may induce genetic and/
or epigenetic changes to the target cells [38].
Exosomes are currently believed to enter recipient cells via inter
nalization. Exosomes are likely to end up in endosomes after entering
the cell throughexosome-endosome membrane fusion. In addition,
exosomes can escape from endosomes and can be transported into the

2.1.4. Exosomal cargos for intercellular communication
Throughout biogenesis, exosomes are loaded with lipids, proteins,
and nucleic acids [48]. Lipids such as sphingomyelin, cholesterol,
desaturated lipids, phosphatidylserine, and ceramide form bilayer
structure of the exosomal membrane [49]. Due to the very small exo
somal size, they are deprived of organelles such as ribosomes or mito
chondria. However, they comprise plentiful RNAs including coding
RNAs as mRNA and ncRNAs, as miRNA, lncRNA and transfer RNA
(tRNA), in addition to several cytokines [29]. These NVs also contain
plenty of different proteins (as HSPs, cytoskeletal proteins, adhesion
molecules, membrane transporter and fusion proteins). These cargos are

Table 1
Differences between exosomes, microvesicles and apoptotic bodies.
Characters

Exosomes (NVs)

Microvesicles (MVs)

Apoptotic bodies (ABs)

Size (nm)
Shape
Formation
mechanism
Cargos

30–150
Regular
Inward budding of the MVB membrane

100–1000
Variable
Outward budding of the PM

50 to 5000
Variable
generated from the PM during apoptosis late phases

Genetic materials: mRNAs, ncRNAs and
miRNAs.
Lipids and proteins
[9,29,30]

Proteins, lipids, nucleic acids & other
molecules

Cellular organelles, intracellular fragments & cytosolic
components

[31]

[26,32,33]

Ref.

MVB: multivesicular body; PM: plasma membrane; mRNA: messenger ribonucleic acid; ncRNA: non-coding ribonucleic acid; miRNA: micro ribonucleic acid.
3
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Fig. 1. Exosomal biogenesis and release.
[Exosome biogenesis starts with the formation of an early endosome through inward budding of the plasma membrane, followed by the formation of a late endosome
containing various ncRNAs and proteins. The late endosome then matures to form MVBs. Finally, MVBs fuse with the plasma membrane and release their ILVs as
exosomes. Exosomes can be taken up by the target cell either through fusion with the plasma membrane or through endocytosis and control its activity after being
secreted into the extracellular matrix by the parent cell. Also, they can mediate their actions via “receptor-ligand” interactions at the target cell.
MVB: multivesicular bodies; ILV: intraluminal vesicles; miRNA: microRNA; lncRNA: long noncoding RNA]

Fig. 2,. Different exosomes isolation techniques; A) Differential ultracentrifugation, B) Density gradient ultracentrifugation, C) Filtration, D) Co-precipitation, E)
Immunoaffinity capture.

specific to the cell of origin and are responsible for the intercellular
communications [50].
After their discharge from the parent cells they start their navigation
in which some of them remain intact for a short time period then the
membrane breaks up releasing the enclosed cargos. These bioactive

cargos as interleukin-1ß, several growth factors as transforming growth
factor (TGF-ß), fibroblast growth factor (FGF), vascular endothelial
growth factor (VEGF) and others become free and ready for direct
binding to specific receptors on the target cells in order to induce spe
cific stimuli [51]. After recognition by the target cells, the exosomes can
4
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fuse with the PM of the receiver cell and be internalized via either
endocytosis or micro-pinocytosis [52]. On one hand, mRNAs found in
exosomes, can be translated into specific proteins in target cells, on the
other hand, miRNAs and lncRNAs navigating within exosomes, could
inhibit expression of certain genes and regulate other biological mech
anisms in these cells. These findings revealed the role of exosomes as
vehicles for genetic information to be exchanged between cells [53].

Table 2
ncRNA and lncRNA Criteria for Classifications
Criteria

Ref.

ncRNA
Size/shape

2.1.5. Exosomes relation to carcinogenesis
Tumor derived exosomes (TEXs) are strongly evidenced to play chief
roles in carcinogenesis [54]. In the TME, bioactive molecules can be
transferred within exosomes between stromal cells, immune cells and
tumor cells to allow the escape of cancer cells from immune response
and thus generating immune resistance [55]. TEXs are capable of
inhibiting natural killer (NK) cells and interfering with monocyte dif
ferentiation [56]. Also, TEXs can transfer the inhibition of production of
type I interferon from epidermal growth factor receptor (EGFR) to the
host macrophages leading to decreasing immunity of cancer patients
[57]. They also promote growth of tumor cells by inhibition of mito
chondrial oxidative phosphorylation, leading to upregulating glycolysis
and glutamine dependent reduction carboxylation in malignant cells
[10].
Additionally, TEXs can contribute in tumor metastasis through
epithelial-to-mesenchymal transition (EMT) regulation and extracel
lular matrix (ECM) alteration [58]. The induction of EMT and its con
trary mesenchymal-to-epithelial transition (MET) is a type of cellular
plasticity throughout tumor progression and metastasis. EMT means
epithelial cells gaining mesenchymal characteristics making them able
to travel separately, survive in the circulation, and at the end invade a
distant organ. On the contrary, for metastatic growth, MET takes place
to regain epithelial traits and produce a secondary tumor [59]. All these
complicated communications are induced during cell–cell contacts and
through secreted bioactive molecules mediated by exosomes [13].
It’s noteworthy here that TEXs have been highlighted to mediate
tumorigenesis and metastasis via what’s known as “Seed-Soil theory”
[60]. That theory suggests that primary tumors release significant
amount of exosomes carrying various invasion-promoting factors, which
enables them to act as the driving force preparing the soil for the met
astatic seeds [61,62]. In such way, TEXs contribute to developing a
cancer-favorable microenvironment in the pre-metastatic niches (PMNs)
[60].

Function

Short/small
Long/large
Circular
Housekeeing
Regulatory

lncRNA
Sense
Genome location

Antisense
Intronic
Intergenic
Bidirectional
Transcriptional
regulators
Sponge or decoy

In different cellular
compartments

Signaling
regulators
Molecular guiding
Molecular scaffold

miRNA < 20 nt
lncRNA > 200 nt
circRNA
rRNA, tRNA
miRNA, lncRNA,
circRNA
overlapping regions, for
epigenetic alteration
from opposite directions,
located in the exons
positioned in the intronic
region
LINC RNA, transcribed
begins in opposite directions

[64]
[64]
[64]
[65]
[65]

[67]
[68]
[69]
[70]
[69]

block transcription

[71]

bind miRNA or mRNA
transcription stimulation,
modulating chromatin
structure
induce epigenetic alterations
modifying chromatin
structure
regulate gene expression

[72]
[19]
[21]
[20]

miRNA: micro ribonucleic acid; lncRNA: long non-coding ribonucleic acid;
circRNA: circular ribonucleic acid; rRNA: ribosomal ribonucleic acid; tRNA:
transfere ribonucleic acid; LINC RNA: long intergenic non-coding ribonucleic
acid.

where start sites of intron transcription could start and end just before
exon regions, they have a significant role in epigenetic alterations on the
same chromosomes [67]. Antisense lncRNAs, are transcribed from
opposite directions and are located within exons [68]. Long intergenic
ncRNAs are transcribed distinctly, in which ncRNAs do not overlap with
protein coding genes [70]. Intronic lncRNAs are positioned in the
intronic regions. Similar to antisense lncRNAs, bidirectional lncRNAs
are characterized by having a starting site that begins in opposite di
rections, but, extend to 1 kb of the promoter region of the mRNA protein
code sequence [69].
In different cellular compartments, we can find lncRNAs and their
specific position is strictly linked with their function. They mainly act as
transcriptional regulators and can be classified according to their func
tion as sponge/decoy, scaffold, guide or signaling regulators [71]. The
decoy/sponge action is a mechanism to block transcription and trans
lation of DNA or RNA via binding transcription factors designed for
transcription activation, and hinder them from reaching their target
causing inactivation of their function [72]. Regarding sponging mech
anism, LncRNAs can bind to miRNAs competitively via miRNA response
elements (RNAs that regulate and communicate with each other by
competing for a limited pool of miRNAs), limiting the amount of miR
NAs that bind to mRNAs and controlling the expression of miRNAs'
downstream target genes at the posttranscriptional level [74]. Working
as molecular scaffold, lncRNAs regulate gene expression by assembling
several proteins together to make functional ribonucleoprotein com
plexes. This affects transcription; either by activation in a specific po
sition of the genome via gathering particular proteins, or by deactivation
via targeting genomic suppressors [20]. Regarding their role as signal
ling molecules; transcription can be stimulated by directing transcrip
tion factors to specific genes and also have a role in modulating
chromatin structure [19]. In such way, gene’s activity can be modulated
by the action of molecular guiding of lncRNAs as they can induce
epigenetic alterations via modifying chromatin structure. This can be
accomplished by lncRNAs interaction or migration to certain gene

2.2. Non-coding RNAs
Only a small ratio of the mammalian genome is transcribed into
mRNA, while the majority is transcribed into ncRNAs [21]. NcRNAs
participate in various important biological functions, at transcriptional
level they control gene expression, RNA processing and translation. In
addition, they take care of genome against foreign nucleic acids and
guide DNA synthesis [63]. NcRNAs have many classifications, regarding
to size and shape they can be divided into short (small) and long (large)
ncRNAs up to 200 nucleotides, in which linear forms (lncRNAs) can be
differentiated from circular forms by appearance [64]. Regarding to
function they are categorized as housekeeping RNAs (as rRNA and
tRNA) and regulatory RNAs (as miRNA, lncRNA and circular RNA
(circRNA)) [65]. Despite of their noncoding properties and annotating
them as transcriptional noises they carry important information, so
became major source for biomarkers of certain biological events and can
be used as therapeutic targets in many diseases [66]. The charactarestics
of various types of ncRNAs are given in Table 2.
2.2.1. Long non-coding RNA
Long non-coding RNA is a subtype of ncRNAs with more than 200
nucleotides in length [73]. They can be classified according to genomic
locations into 5 classes: sense, antisense, intronic, intergenic and bidi
rectional lncRNAs [72]. Sense lncRNAs possess overlapping regions,
5
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locations of specific enzymes to change chromatin architecture [21].
Most of malignant genetic mutations points to non-coding gene
segments, that encode for lncRNAs and this proves the role of lncRNAs in
cancer initiation and progression [18].

ovarian cancer, either by stimulation or by inhibition such as H19,
HOTAIR, PVT1, Urothelial Cancer Associated 1 (UCA1) and Metastasis
Associated Lung Adenocarcinoma Transcript 1 (MALAT1) [88]. HOTAIR
maintains the stemness of ovarian cancer stem cells by sponging miR206, resulting in up-regulated production of T-box transcription factor
3 (TBX3), which enhances ovarian cancer stem cells stemness [89]. In
ovarian cancer, PVT1 stimulates cell proliferation and invasion by
controlling miR-133a [90]. UCA1 acts as a molecular sponge to down
regulate miR-143, leading to partial cessation of translational repression
of its target gene FOS-like antigen 2 (FOSL2) [91]. H19 was found to be
upregulated in ovarian cancer patients compared to healthy subjects,
and was supposed to act as a competitive endogenous RNA (ceRNA) to
stimulate TGF-β-associated EMT, through sponging miR-370-3p and
thus, aids malignant cells invasion and migration [92].

2.2.2. LncRNAs in different types of cancer
2.2.2.1. Breast cancer. Breast cancer is the most common malignancy in
women worldwide and the second prominent cause of cancer related
mortality in women. It shows deregulation in more than one lncRNA
such as, but not limited to, HOXC gene cluster Transcript Antisense
Intergenic RNA (HOTAIR) and H19-Igf2 locus lncRNA (H19) [75].
HOTAIR, the 2.2 kb long, was found to be upregulated in breast cancer
patients, acting via competitive binding to the tumor suppressor gene
BReast CAncer gene 1 (BRCA1), leading to epithelial cells alteration
[76]. As for H19, myelocytomatosis (c-Myc) transcription factor, a wellknown proto-oncogene was suggested to regulate the transcription of
H19 (a 2.7 kb lncRNA) when it binds to box E region located on H19
promoter [77]. Interestingly, in a recent study from our lab, LINC00511
serum expression was found to be 312-fold higher in BC patients
compared to healthy control subjects. [78]. All these data highlight the
strong potential of lncRNAs as novel diagnostic/prognostic biomarkers
for breast cancer.

2.2.2.5. Lung cancer. Lung cancer is considered one of the highest
mortality rate cancers, among all types [93]. Two sub-types of lung
cancer are there, which are small cell lung cancer (SCLC) and non-small
cell lung cancer (NSCLC), depending on the morphological variations
and differentiation degree, but NSCLCs represent about 85% of all lung
cancer diagnosed cases [94]. Upregulation of the lncRNA Non-Coding
RNA Activated By DNA Damage (NORAD) levels were observed in
NSCLC tissues and cell lines. It controls the PI3K/Akt/mTOR signaling
pathway, via acting as a ceRNA, against miR-520a-3p [95]. UbiquitinFold Modifier Conjugating Enzyme 1 (UFC1) is a lncRNA detected in
NSCLC patients sera. UFC1 reduces apoptosis, enhances proliferation,
migration and invasion of NSCLC cells through suppression of Phos
phatase and tensin homolog (PTEN) via Enhancer Of Zeste 2 Polycomb
Repressive Complex 2 Subunit (EZH2) [96].

2.2.2.2. Gastric cancer. Gastric cancer is ranked the fifth most diag
nosed tumor and the third malignancy that causes death all over the
world [79]. Again comes here the lncRNA HOTAIR which is considered
among the most observed lncRNAs that aids in progression and metas
tasis of gastric cancer through sponging miR-1227-5p wich targetsCol
lagen Type V Alpha 1 Chain (COL5A1) resulting in an increased
expression of COL5A1. In the extracellular matrix, COL5A1 increases
collagen density and promotes EMT, ultimately leading to more tumor
cells proliferation and migration [80]. Also, lncRNA plasmacytoma
variant translocation 1 (PVT1) was found to be upregulated in gastric
cancer cell lines.Acting through lncRNA-miRNA-mRNA axis, PVT1
sponges miR-30a-5p and as a result the expression of N-cadherin
(transmembranous protein expressed by several tissues and functions by
regulating cell-cell adhesion) increases. In addition, PVT1 was also
found to have an effect on E-cadherin expression that promotes EMT and
thus, aids in gastric tumors invasion and metastasis [81].

2.2.2.6. Pancreatic cancer. It has been anotated the King of Cancers, due
to its high lethality. Pancreatic cancer possesses an overall five-year
survival rate of 8% only, and is characterized by rapid metastasis, bad
prognosis and rarely responds to therapy [97]. The antisense lncRNA
HOXA transcript at the distal tip (HOTTIP) is elevated in pancreatic
cancer patients, enhancing tumor cells proliferation and metastasis,
through activation of Wingless-related integration site (Wnt)/β-catenin
pathway and regulating HOXA9 levels [98]. The lncRNA Taurine UpRegulated 1 (TUG1) inhibits miR-29c, leading to increasing matrix
metalloproteinases (MMPs) MMP2 and MMP9 resulting in an increased
cancerous cells ability for invasion and metastasis [99]. H19 lncRNA,
that is involved in many types of cancer, including pancreatic cancer,
regulates the transcription factor E2F-1 expression, via sponging miR675, and consequently promoting tumor cells invasion and metastasis
[100].
Here in Table 3, we highlight the functional role of lncRNAs in many
types of cancer and how they aid in cancer initiation, progression and/or
metastasis.

2.2.2.3. Hepatocellular carcinoma. It is the most detected subtype of
liver malignancy and considered the sixth most prevailing cancer. Many
lncRNAs have been reported to be involved in liver carcinogenesis [82].
One example is the lncRNA highly upregulated in liver cancer (HULC),
that works on miR675-PKM2 axis and increases the expression of cyclin
D, resulting in an enhancement of cancer stem cells growth through
sirtuin (silent mating type information regulation 2 homolog) 1 (Sirt1)
upregulation [83]. Also, higher levels of Nuclear Enriched Abundant
Transcript 1 (NEAT1) was observed to be associated with progression
and metastasis of hepatocellular carcinoma. Silencing of NEAT1 stops
proliferation and invasion of tumor cells in HepG2 and Hep3B cells [84].
In addition, NEAT1 was found to increase the resistance of hepatocel
lular cancer cells against sorafenib (an antitumor drug) through acti
vating tyrosine-protein kinase Met/serine-threonine kinase 1 (c-Met/
Akt) axis that negatively regulate miR-335 [85]. On the other hand,
repression of NEAT1 enhances the sensitivity of hepatocellular cancer
cells towards antitumor activity of CD8+T cells through regulation of
miR-155 levels [86].

2.3. Exosomal-LncRNA in colorectal cancer
2.3.1. CRC molecular pathophysiology:
The majority of colorectal tumors originate from adenomatous
polyps, this makes polyps identification, diagnosis and resection a chief
part of endoscopy practice. Adenomas recognition and other colorectal
polyps detection have increased significantly with the emergence of
bowel tumor screening programs [101]. Morphologically, a polyp ap
pears as an abnormal protrusion from a mucosal lining. Adenomas are
considered benign neoplasms of the large bowel mucosa and are rarely
symptomatic, however, their importance comes from that they are the
source lesion for the majority of colorectal tumors [102].
On molecular basis, CRC is featured by genetic instability, that can
originate from at least two distinct mechanisms, namely chromosomal
instability and/or microsatellite instability [103]. Chromosomal insta
bility is characterized by remarkable changes in structure and number of

2.2.2.4. Ovarian cancer. Ovarian canceris assumed to have the highest
lethality among gynaecologic cancers worldwide. Due to its late diag
nosis it is detected at advanced stages, so it is characterized by poor
prognosis and low survival rates, beside its resistance to chemothera
peutic agents [87].Several lncRNAs were found to have different roles in
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instability could take place due to malfunctioning DNA mismatch repair
defects, causing silencing of various tumor suppressor genes such as
MutL homolog 1 (MLH1) [105].

Table 3
The functional roles of different LncRNAs in different cancer types
LncRNA

Target tumor/
s

Pathway

Ref

HOTAIR

Breast

competitive binding to BRCA1 leading to
epithelial cells alteration
sponging miR-1227-5p, increasing COL5A1
expression; promoting EMT & more tumor
cells proliferation and migration
sponging miR-206, resulting in up-regulated
production of TBX3, which enhances
ovarian cancer stem cells stemness
regulated via c-Myc, when it binds to box E
region located on H19 promoter
ceRNA to stimulate TGF-β, sponging miR370-3p, aiding malignant cells invasion &
migration
regulates E2F-1 expression by sponging
miR-675 & promoting tumor cells invasion
& metastasis
sponges miR-30a-5p increasing N-cadherin
expression & aids in gastric tumors invasion
and metastasis
stimulates cell proliferation and invasion by
controlling miR-133a
works on miR675-PKM2 axis & increases
cyclin D expression, cancer stem cells
growth through Sirt1 upregulation
progression & metastasis & resistance
against sorafenib, through activating c-MetAkt axis, negatively regulate miR-335
controls the PI3K/Akt/mTOR signaling
pathway via acting as a ceRNA against miR520a-3p
reduces apoptosis, enhances proliferation,
migration & invasion of NSCLC cells
through suppression of PTEN via EZH2
tumor cells proliferation & metastasis
through activation of Wnt/β-catenin
pathway and regulating HOXA9 levels
inhibits miR-29c, increasing MMP2, MMP9,
increasing cancerous cells invasion &
metastasis
molecular sponge to downregulate miR143, leading to partial cessation of
translational repression of its target gene
FOSL2

[76]

Gastric
Ovarian
H19

Breast
Ovarian
Pancreatic

PVT1

Gastric
Ovarian

HULC

Hepatocellular

NEAT1
NORAD

NSCLC

UFC1
HOTTIP

Pancreatic

TUG1
UCA1

Ovarian

2.3.2. LncRNAs affecting CRC signaling pathways
In fact, over the past few years, a growing body of evidence has
proven the role of lncRNAs in both development and progression of
many types of cancers, including CRC [106]. They play a cheif role in
mediating CRC tumorigenicity, through several cellular signaling path
ways such as Wnt/β-catenin, phosphoinositide 3-kinase/ protein kinase
B (PI3K/AKT), the Janus Kinase 2/signal transducer and activator of
transcription 3 (JAK2/ STAT3), the tumor protein 53 (p53), and V-raf
murine sarcoma viral oncogene homolog B/Kirsten rat sarcoma viral
oncogene (BRAF/KRAS) mutation signaling pathways [107], [108,109].
The Wnt/β-catenin pathway, The lncRNA colon cancer-associated
transcript-2 (CCAT2) stimulates Wnt cascade activity through T cell
factor 7L2 (TCF7L2) leading, eventually, to MYC oncogenic activation
[110]. Tumor growth can also be activated by Cancer Susceptibility 11
(CASC11) lncRNA that enhances Wnt/β-catenin signaling action via
targeting heterogeneous nuclear ribonucleoprotein K (hnRNP-K) in CRC
cells [111]. LncRNAs can activate Wnt/β-catenin cascade through
sponging or binding to particular miRNAs, some of these lncRNAs are
zinc finger E-box-binding protein 1-Antisense RNA1 (ZEB1-AS1), H19,
Colorectal Neoplasia Differentially Expressed (CRNDE), HLA Complex
Group 18 (HCG18), HOTAIR, prostate cancer-up-regulated long non
coding RNA 1 (PlncRNA-1) and X-inactive specific transcript (XIST)
[107].
Similarly, the lncRNA hepatocyte nuclear factor 1 homeobox Aantisense RNA 1 (HNF1A-AS1) can control the expression of β-catenin,
cyclinD1, and c-myc, all of which have important roles in the Wnt
signaling pathway [112]. Likewise, NEAT1 indirectly activates the Wnt/
β-catenin signaling pathway through regulating DEAD-Box Helicase 5
(DDX5) protein [113]. On the other hand, Branched Chain Amino Acid
Transaminase 1 (BCAT1) suppresses tumorigenicity by downregulating
the expression of β-catenin in CRC cells [114].
PI3K/AKT signaling pathway is another pathway that regulates CRC
tumor progression and, can be regulated by numerous lncRNAs.
LncRNA-422 is considered as tumor suppressor as it inhibits cell pro
liferation, migration and invasion through regulating PI3K/AKT/mTOR
pathway in CRC [115]. On the contrary, PlncRNA-1 performs its pro
liferative properties through targeting the PI3K/AKT signaling cascade
in CRC [116]. Besides, TTN-AS1 promotes CRC proliferation via pro
moting miR-497-mediated PI3K/AKT/mTOR signaling pathway [117].
JAK2/STAT3 signaling pathway, like PI3K/AKT pathway, possesses
a regulatory impact on motivating malignant progression in CRC [118].
Also, this signaling pathway aids in the persistent growing of cancer
stem cells after radiotherapy in CRC [119]. The HOTAIR/miR-214/
ST6GAL1 axis regulates the malignant performance of CRC cells.
ST6GAL1 is considered as an essential enzyme that forms α 2, 6-linked
sialic acids which is the main structure of sialylated glycoprotein. Un
usual modification of c-Met, with α 2, 6-sialic terminal structure causes
c-Met activation that participates in initiation of cancer malignancy and
also in CRC progression through JAK2/STAT3 pathway. In addition
ST6GAL1 and HOTAIR were observed to act as direct targets of miR-214,
however, HOTAIR modulates ST6GAL1 expression through sponging
miR-214 that acts as a suppressor for colorectal malignancy. [120].
p53 pathway represents an important pathway that controls cancer
cells proliferation and apoptosis [121]. Also, p53 pathway is affected by
certain lncRNAs to regulate the behavior of CRC through modulating
tumor cells growth and survival. The lncRNA p53 upregulated regulator
of P53 levels (PURPL) have an inhibitory effect on basal p53 levels via
interaction with MYBBP1A protein, the p53 stabilizer, with CRC
tumorigenicity enhancement [122]. Long intergenic non-coding RNA
regulator of reprogramming (LINC-RoR) regulates p53 levels, causing
enhanced cancer cells apoptosis with suppressing tumor cells prolifer
ation [123]

[80]
[89]
[77]
[92]
[100]
[81]
[90]
[83]
[85]
[95]
[96]
[98]
[99]
[91]

LncRNA: long non-coding RNA; HOTAIR: Homeobox C gene cluster Transcript
Antisense Intergenic RNA; BRCA1: Breast Cancer gene 1; miR-1227-5p: micro
RNA-1227-5p; COL5A1: Collagen type V Alpha 1 chain; EMT: Epithelial-toMesenchymal Transition; miR-206: micro RNA-206; TBX3: T-BoX transcription
factor 3; H19: H19-Igf2 locus lncRNA; c-Myc: Cellular Myelo-cytomatosis;
ceRNA: competing endogenous RNA; TGF-β: Transforming Growth FactorBeta; miR-370-3p: micro RNA-370-3p; miR-675: micro RNA-675; PVT1: Plas
macytoma Variant Translocation 1; miR-30a-5p: micro RNA-30a-5p; N-cad
herin: neural cadherin; miR-133a: micro RNA-133a; HULC: Highly Up-regulated
in Liver Cancer; miR675-PKM2: micro RNA 675-pyruvate kinase M2; Sirt1:
sirtuin (silent mating type information regulation 2 homolog) 1; NEAT1: Nuclear
Enriched Abundant Transcript 1; miR-335: micro RNA-335; NORAD: Noncoding RNA Activated by DNA Damage PI3K: Phosphoinositide 3-kinases;
miR-520a-3p: micro RNA-520a-3p; UFC1: Ubiquitin-Fold modifier Conju
gating enzyme 1; NSCLC: Non-Small Cell Lung Cancer PTEN: Phosphatase and
TENsin homolog; EZH2: Enhancer of Zeste 2 polycomb repressive complex 2
subunit; HOTTIP: HOXA Transcript at the distal tip; Wnt: Wingless-related
integration site; HOXA9: Homeobox protein A9; TUG1: Taurine Up-regulated
Gene 1; miR-29c: micro RNA-29c; MMP2: Matrix Metallo-Protein 2; MMP9:
Matrix Metallo-Protein 9; UCA1: Urothelial Cancer Associated 1; miR-143: micro
RNA-143; FOSL2: FOS-Like antigen.

chromosomes, these changes include deletions, additions, translocations
and other rearrangement changes representing a characteristic hallmark
of malignancies that follow adenoma-carcinoma sequence. An example
of choromsomal instability is mutations in adenomatous polyposis coli
(APC) tumor suppressor gene [104]. On the other hand, microsattelite
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BRAF/KRAS mutation signaling pathway is an another pathway
involved in CRC [124]. Interestingly, KRAS mutation has been shown to
alter the composition of non-coding RNAs secreted from exosomes
which influence cell–cell communication [125].

Table 4
The functional roles of different LncRNAs in CRC.

2.3.3. LncRNAs Promoting CRC Invasion and Migration through EMT
regulation
EMT is the route that enhances tumor cells migration and metastasis,
as epithelial cells gain mesenchymal characteristics [126]. In addition,
EMT was proven to play an important role in chemotherapeutic agents
resistance [127]. EMT-mediated invasion and migration are regulated
by lncRNAs, primarily, through their regulation of Wnt/β-catenin
signaling and/or EMT associated transcription factors such as snail
family transcriptional repressor 2 (SLUG), ZEB1 and ZEB2, TWISTrelated protein 1 (TWIST), snail family transcriptional repressor 1
(SNAI1) [128]. For example, lncRNA SNHG6 induces EMT through
regulating ZEB1/miR-101-3p axis [129]. In addition, XIST acts as ceRNA
and modulates ZEB1 expression through competing with miR-200b-3p
leading to CRC metastasis [130]. Likewise, H19 inhibits Vimentin,
ZEB1, and ZEB2 expression through competing with miR-138 and miR200a [131]. Recently, β-1,3-galactosyltransferase 5-antisense 1
(B3GALT5-AS1) downregulates miR-203 expression, via binding
directly to its promoter region, targeting ZEB2, SNAI2 and therefore,
enhancing EMT and liver metastasis in CRC [132]. LINC01413/hnRNPK/ZEB1 axis induces Yes-associated protein 1 (YAP1) and its paralog
PDZ-binding motif (TAZ) YAP1/TAZ1 translocation leading to upregu
lating cell proliferation and EMT in CRC [133]. As a ceRNA, TUG1
lncRNA stimulates EMT and metastasis in CRC, through β-catenin
signaling, upregulating CEll Migration Inducing Protein (CEMIP)
expression and downregulating miR-600 expression [134]. Also, H19/
miR-29b-3p/PGRN (Progranulin; pleiotropic growth factor protein)
axis accelerates EMT in CRC through the Wnt signaling pathway as well
[135].
In addition, lncRNAs can regulate EMT through epigenetics modifi
cations as DNA methylation, histone demethylation and histone acety
lation play chief role during EMT [136]. HOXD-AS1 enhances tumor
growth and EMT through modulating the expression of the proteins
AEG-1 and EZH2 (protein has been demonstrated as an important factor
in histone methylation) in CRC cells by competing for miR-217 [137].
Fortunately, the epigenetic regulator lncRNA natural occurring brainderived neurotrophic factor antisense (BDNF-AS) acts as a tumour sup
pressor in CRC progression, by inhibiting EMT-induced migration,
through binding to EZH2 and histone H3K27me3 demethylase within
the GSK-3 promoter and downregulating GSK-3 expression [138].
Finally, when controlling the expression of miR-129–5p and the protein
coding gene DNA Methyltransferase 3 Alpha (DNMT3A), hypoxia
inducible factor 1A antisense RNA 2 (HIF1A-AS2) can bind to miR129–5p and positively affects EMT-mediated cell migration and invasion
potential [139]. Table 4 summarizes the lncRNAs interrelated with CRC,
together with their mechanisms of action.

LncRNA

Target

Pathway

Ref

CCAT2

TCF7L2

[110]

CASC11

hnRNP-K

ZEB1-AS1

miR-181a-5p

H19

miR-200a

Stimulates Wnt cascade activity
through T cell factor 7L2 (TCF7L2)
leading to MYC oncogenic activation
Enhances Wnt/β-catenin signaling
action via targeting heterogeneous
nuclear ribonucleoprotein K (hnRNPK) in CRC cells
Enhances proliferation by stimulating
Wnt/β-catenin signaling action via
regulating miR-181a-5p
Enhances proliferation by stimulating
Wnt/β-catenin signaling action via
regulating miR-200a
Enhances migration & invasion by
stimulating rat sarcoma/mitogen
activated protein kinase (RAS/
MAPK) signaling pathway through
regulating RAS
Enhances proliferation, invasion &
EMT through stimulating Wnt/
β-catenin signaling by regulating
miR-29b-3p/PGRN
Enhances proliferation and EMT
through regulating miR-138/
Vimentin, miR-200a/ZEB1,ZEB2
Enhances proliferation and
chemoresistance through stimulating
Wnt/β-catenin pathway via
regulating miR-181a-5p
Enhances proliferation and invasion
through stimulating Wnt/β-catenin
pathway via regulating miR-1271
Enhances proliferation and
chemoresistance through stimulating
Wnt/β-catenin pathway via
controlling miR-203a-3p
Enhances proliferation, metastasis
and chemoresistance through
stimulating JAK2/STAT3 pathway
via controlling miR-214
Enhances proliferation, migration
and invasion through stimulating
PI3K/AKT pathway via regulating
PI3K
Enhances proliferation, migration,
invasion and EMT through
stimulating Wnt/β-catenin pathway
via regulating miR-204
Enhances proliferation and invasion
through stimulating Wnt/β-catenin
pathway via regulating miR-34a
A ceRNA, modulates ZEB1 expression
through competing with miR-200b3p leading to CRC metastasis
Enhances proliferation and poor
prognosis through activating Wnt/
β-catenin pathway
Indirectly activates the Wnt/
β-catenin signaling pathway through
regulating DDX5 protein
Suppresses tumorigenicity by
downregulating the expression of
β-catenin in CRC cells
Tumor suppressor inhibits cell
proliferation, migration and invasion
through regulating PI3K/AKT/mTOR
pathway in CRC
Promotes CRC proliferation via
promoting miR-497-mediated PI3K/
AKT/mTOR signaling pathway
Promotes CRC cells proliferation and
tumor progression by regulating cMet metabolic levels through JAK2/
STAT3

RAS

miR-29b-3p

miR-138
miR-200a
CRNDE

miR-181a-5p

HCG18

miR-1271

HOTAIR

miR-203a-3p

miR-214

PlncRNA-1

PI3K

miR-204

XIST

miR-34a
miR-200b-3p

HNF1A-AS1

2.4. Exosomal-LncRNA in colorectal carcinogenesis
Cancer-derived or stromal cells-derived exosomes have been shown
to remodel the local TME via moving their cargos from one cell to
another, hence stimulating cancer cell growth and distant metastasis
[140]. As mentioned before, ncRNAs, such as miRNAs, lncRNAs, and
circRNAs have been shown to play important roles in controlling CRC
growth and drug resistance, and could be used as diagnostic and prog
nostic biomarkers for CRC [141]. Exosomes derived from a hypoxic CRC
atmosphere promote tumorigenesis by sending Wnt4 mRNA to normoxic
CRC cells, leading to ß-catenin stimulation. The Wnt/β-catenin signal
ling pathway is critical for metazoan production and is abnormally
activated during CRC, encouraging stem cell proliferation, angiogenesis,
and endothelial cell migration [142].
Exosome-derived HOTAIR has also been discovered to serve as an

NEAT1

β-catenin
cyclinD1
c-myc
DDX5

BCAT1

β-catenin

LncRNA422

m-TOR

TTN-AS1

miR-497

ST6GAL1

c-Met

[111]

[107]
[107]
[107]

[135]

[131]
[107]

[107]
[107]

[107]

[116]

[107]

[107]
[130]
[112]
[113]
[114]
[115]

[117]
[120]

(continued on next page)
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activator of the β-catenin/Wnt signalling cascade. It is one of the most
widely identified IncRNAs in the development of intestinal cancers
[143]. The function of lncRNA H19 and cancer-associated fibroblasts
(CAFs) in CRC stemness and resistance to oxaliplatin is well established,
as well as the molecular mechanism by which CAF-derived exosomes
triggered Wnt/β-catenin signalling, via transferring exosomal H19
[144]. Besides, exosomes have been identified as the key carriers of the
lncRNA 91H, which aids tumour migration and invasion by altering
HNRNPK expression. Furthermore, exosomal 91H levels in the serum of
CRC patients was found to be substantially higher compared to healthy
subjects, and this was associated with aggressive tumour invasion and
metastasis [145]. In addition, exosomal CRNDE-h levels were reported
to be related to factors that predict negative clinical outcomes, such as
distant metastasis and positive lymph node metastasis [146].
Interestingly, low levels of exosomal lncRNA HOTTIP have been
reported to be associated with poor overall survival of CRC patients
[147]. In contrast, increased expression of UCA1 has been reported in
cetuximab-resistant CRC cells and their exosomes. Moreover, exosomes
derived from these cetuximab-resistant cells have been found not only to
alter UCA1 expression, but also to transmit cetuximab-resistance to
originally sensitive cells. These findings highlight how UCA1-carrying
exosomes are implicated with drug-resistance, and could be a poten
tial novel therapeutic target [148].

Table 4 (continued )
LncRNA

Target

Pathway

Ref

PURPL

MYBBP1A
protein

[122]

LINC-RoR

p53

SNHG6

miR-101-3p

B3GALT5AS1

miR-203

LINC01413

YAP1
TAZ1

TUG1

CEMIP
miR-600

HOXD-AS1

miR-217

BDNF-AS

EZH2
histone
H3K27me3
demethylase

HIF1A-AS2

miR-129–5p
DNMT3A

Enhances tumorigenicity through
inhibition of basal p53 levels via
interaction with MYBBP1A protein,
the p53 stabilizer
Regulates p53 levels, causing
enhanced cancer cells apoptosis with
suppressing tumor cells proliferation
Induces EMT through regulating
ZEB1/miR-101-3p axis
Downregulates miR-203 expression,
via binding directly to its promoter
region, targeting ZEB2, SNAI2 and
therefore, enhancing EMT and liver
metastasis in CRC
Induces YAP1/TAZ1 translocation
through regulating LINC01413/
hnRNP-K/ZEB1 axis leading to
upregulating cell proliferation and
EMT in CRC
A ceRNA that stimulates EMT and
metastasis in CRC, through β-catenin
signaling, via upregulating CEMIP
expression and downregulating miR600 expression
Enhances tumor growth and EMT
through modulating the expression of
the proteins AEG-1 and EZH2 in CRC
cells by competing for miR-217
A tumour suppressor in CRC
progression, inhibits EMT-induced
migration, through binding to EZH2
and histone H3K27me3 demethylase
within the GSK-3 promoter and
downregulating GSK-3 expression
Controls miR-129–5p and DNMT3A
expression & positively affects EMTmediated cell migration and invasion
potential

[123]
[129]
[132]

[133]

[134]

[137]

2.5. Exosomal-LncRNAs as CRC Diagnostic and/or prognostic markers
[138]

Recently, the rate of CRC detection has increased, with the use of
fecal occult blood test (FOBT) and colonoscopy. FOBT (a lab test used to
check stool samples for hidden (occult) blood) is simply operated and is
of low cost, but its sensitivity is low. As, tumors often have less tendency
towards bleeding, false-negative FOBT results occurs [149]. Colonos
copy is the gold standard for colorectal neoplasia screening, but it is a
traumatic painful operation with a high cost, rendering it unsuitable for
large-scale screening [101]. Finally, blood tests for the tumor markers
carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA19-9), and
CA242, have low sensitivity, which means they don't meet the clinical
diagnostic criteria [150].
The molecular content of tumor derived exosomes can provide spe
cific molecular markers (cargos) for early diagnosis and prognosis, since
all cancer cells produce massive amounts of exosomes from an early
stage [151]. As a result, researchers believe that circulating exosomes
can provide a useful tool for noninvasive cancer diagnosis and/or
prognosis [152]. Furthermore, several CRC studies have shown that
particular circulating exosomes in patients' plasma are linked to poor
prognosis and can be used as accurate CRC diagnostic biomarkers [153].
On the other hand, circulating lncRNAs have been extensively
studied in the prediction and diagnosis of various cancers such as
HOTAIR in cervical cancer [154], UCA1 in breast cancer, gastric cancer,
and NSCLC [155–157], small nucleolar RNA host gene 7 (SNHG7) in
lung cancer [158], and H19 in gastric cancer and NSCLC [159,160],
Exosomal Breast Cancer Anti-Estrogen Resistance 4 (BCAR4) lncRNA
is downregulated in the serum of patients with colon adenoma, relative
to normal subjects. Furthermore, by combining two mRNAs, keratinassociated protein 5.4 (KRTAP 54) and the class 1 melanomaassociated antigen family A (MAGE-A), with this lncRNA, a suitable
panel for CRC diagnosis was developed [161]. Six highly expressed
exosomal lncRNAs LNCV6 (116109, 98390, 38772, 108266, 84003, and
98602) in CRC patients’ plasma, used as novel biomarkers for CRC
[162].
The functional and potential diagnostic exosomal lncRNAs involved
in CRC are listed in Table 5.

[139]

LncRNA: long non-coding RNA; CCAT2: Colon Cancer-Associated Transcript-2;
Wnt: Wingless-related integration site; CASC11: Cancer Susceptibility 11;
hnRNP-K: Heterogeneous nuclear Ribo-Nucleo-Protein K; CRC: colorectal can
cer; ZEB1-AS1: miR-181a-5p: H19: miR-200a: RAS: MAPK: miR-29b-3p: EMT:
PGRN: miR-138: miR-200a: ZEB1: Zinc finger E-Box-binding protein 1-AntiSense 1 ZEB2: Zinc finger E-Box-binding protein 2; CRNDE: Colorectal
Neoplasia Differentially Expressed; HCG18: HLA Complex Group 18; miR-1271:
micro RNA-1271; HOTAIR: Homeobox C (HOXC) gene cluster Transcript Anti
sense Intergenic RNA; miR-203a-3p: micro RNA-203a-3p; miR-214: micro RNA214; JAK2: Janus Kinase 2; STAT3: Signal Transducer and Activator of Tran
scription 3; PlncRNA-1: Prostate cancer-up-regulated long noncoding RNA 1;
PI3K: Phosphoinositide 3-kinase; miR-204: micro RNA-204; XIST: X-Inactive
Specific Transcript; miR-34a: micro RNA-34a; miR-200b-3p: micro RNA-200b3p; ceRNA: competing endogenous RNA; HNF1A-AS1: Hepatocyte Nuclear
Factor 1 homeobox A-Anti-Sense RNA 1; NEAT1: Nuclear Enriched Abundant
Transcript 1; DDX5: DEAD-Box helicase 5; BCAT1: Branched Chain Amino Acid
Transaminase 1; LncRNA-422: long non-coding RNA-422; miR-497: micro RNA497; ST6GAL1: ST6 beta-GALactoside alpha-2,6-sialyltransferase 1; PURPL: p53
Upregulated Regulator of p53 Levels; MYBBP1A: MYB binding protein 1a; LINCRoR: Long Intergenic Non-Coding RNA Regulator Of Reprogramming; SNHG6:
Small Nucleolar RNA Host Gene 6; miR-101-3p: micro RNA-101-3p; miR-203:
micro RNA-203; SNAI2: Snail family transcriptional repressor 2; LINC01413:
long interfering non-coding RNA 01413; YAP1: Yes-Associated Protein 1; TAZ1:
Transcriptional coactivator with pdZ-binding motif 1; TUG1: Taurine Upregulated Gene 1; CEMIP: Cell Migration Inducing Protein; miR-600: micro
RNA-600; HOXD-AS1: homebox D-antisense 1; miR-217: micro RNA-217; AEG1: Astrocyte elevated gene-1; BDNF-AS: Brain-Derived Neurotrophic FactorAntiSense; EZH2: Enhancer of Zeste 2 polycomb repressive complex 2 subunit;
GSK-3: Glycogen Synthase Kinase-3; HIF1A-AS2: Hypoxia Inducible Factor 1A
Anti-Sense RNA 2; miR-129–5p: micro RNA-129-5p; DNMT3A: DNA MethylTransferase 3 Alpha.

2.6. Exosomes as therapeutic targets for CRC treatment
Exosomes, the natural nanosized bio-inspired vesicles secreted by
various cells, have recently been used to deliver a variety of
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during cancer cell growth and proliferation [173]. TAAs are presented
by dendritic cells (DCs), which can then cause TAA-specific immune
responses. DCs secrete exosomes that keep the immune system going
[174]. DCs-derived exosomes (Dex) have been shown to carry major
histocompatibility antigen complex (MHC) proteins and other costimulatory molecules as well as having strong antigen-presenting
properties to stimulate antigen-specific NK cells, T cells, and B cells re
sponses [175]. Besse and coworkers studied the immunotherapeutic ef
fects of Dex in NSCLC patients. In a phase II clinical trial, they employed
MHC-I and MHC-II in combination with interferon gamma (IFN-γ)-Dex
to boost NK cells' anti-tumor activity [176].
It’s important to point here that when incorporating a chemothera
peutic agent such as Dox or paclitaxel within exosomes, these drugs
exhibit a much better stability via extending their circulation time and
protecting them from degradation, with better therapeutic effect and
more tumor accumulation compared to their effects alone [177,178].
Liang and colleagues fused ApoA1, a scavenger receptor type B type 1
(SR-B1) receptor target, to the exosomal surface and loaded functional
miR-26a into exosomes. These engineered-exosomes were delivered to
the SR-B1 liver cancer cell line, where they released the miR-26a and
suppressed cell migration and proliferation [179].
Moreover, it was found that TEXs have a wide range of effects on the
immune function. On one hand, TEX-mediated immune cell function
inhibition leads to tumour growth and host-immune system escape. On
the other hand, TEXs via their surface proteins can stimulate the im
mune system [180]. TEX can interact with the immune system either
directly or indirectly. The interaction between corresponding T cells and
MHC class II peptide complexes (MHC II-peptide), co-stimulatory fac
tors, and adhesion molecules on the exosomal surface are all needed for
direct immune action. The indirect effect comes from the interaction
between surface proteins (integrin or intercellular adhesion molecule 1)
on the TEX and antigen presenting cells of the tumor [181,182].
In addition, the importance of exosome membrane scaffolds and
their protein fraction, known as exosome-scaffold-proteins, derived
from CRC were proved to affect the therapeutic potential of the exo
somes. These proteins are ferritin-based andcontain signal regulatory
protein (SIRP), a CD47 antagonist on tumour cells. Exosomal-mediated
CD47 blockade has a higher therapeutic index for tumour growth inhi
bition than ferritin-SIRP, at the same dose. When compared to proteinscaffold-based nanocages, the therapeutic protein delivery was found to
be improved [183].
In Summary; exosomes, with its lncRNAs cargo, can be considered as
evil players contributing to cancer pathogenesis, or as good players for
CRC diagnosis/prognosis and to deliver loaded therapeutics, in a tar
geted manner, this can be illustarted in Fig. 3.

Table 5
The functional roles of different Exosomal-LncRNAs in CRC.
Exosomal-lncRNA

Function

Ref

HOTAIR
H19

Activates β-catenin/Wnt signalling cascade
CAF-derived exosomes triggered Wnt/
β-catenin signalling, via transferring
exosomal H19
Aids tumour migration and invasion by
altering HNRNPK expression
Positively associated with regional lymph
node metastasis and distant metastasis
Low levels have been found associated with
poor overall survival
Implicated with drug-resistance, and could
represent a potential novel therapeutic
target
Downregulated in colon adenoma patients
sera, relative to normal subjects, used in
CRC dignosis
Up-regulated in CRC patients’ plasma, serve
as potential non-invasive biomarkers for
early CRC diagnosis

[143]
[144]

91H
CRNDE-h
HOTTIP
UCA1
BCAR4
LNCV6 (116109, 98390,
38772, 108266, 84003,
98602)

[145]
[146]
[147]
[148]
[161]
[162]

HOTAIR: Homeobox C (HOXC) gene cluster Transcript Antisense Intergenic
RNA; Wnt: Wingless-related integration site; H19: H19-Igf2 locus lncRNA; CAF:
Cancer-Associated Fibroblast; HNRNPK: Heterogeneous nuclear Ribo-NucleoProtein K; CRNDE: Colorectal Neoplasia Differentially Expressed.
HOTTIP: HOXA Transcript at the distal tip; UCA1: Urothelial Cancer Associated
1; BCAR4: Breast Cancer Anti-estrogen Resistance 4; CRC: colorectal cancer.

therapeutics, including small interfering RNA (siRNA), taxol, and
doxorubicin (Dox), as well as genes as drug co-delivery system [163].
Because of exosomes' unique properties, such as biocompatibility, low
toxicity, circulatory stability, and tumour specificity, as well as high
tumor penetration capacity due to their small nano-size [164], re
searchers have begun to focus on exosomes' potential in treatment of
many cancers.
It’s noteworthy that exosomes have some benefits over conventional
nano-liposomes, namely, lower toxicity and immunogenicity, improved
stability, and longer circulation in vivo [165,166]. Moreover, exosomal
targeting ability to tumour cells is slightly better than liposomes, of
equivalent size, which may be due to endocytosis by recipient cells or
ligands located on the exosomal surface [167]. As a result, exosomes
have a lot of potentials as effective natural therapeutic delivery systems for
drugs. Nanosomes, a drug delivery device first focused on conjugating
gold nanoparticles (GNPs) with the anticancer drug Dox and binding
them to the exosome pH-sensitive hydrazone, were recently created by
pharmaceutics researchers for treatment of lung cancer. These nano
somes exhibited preferential cytotoxicity against lung cancer cells ac
cording to cell viability studies [168]. Moreover, Li and coworkers used
Dox as cargo and demonstrated the ability of exosomes coated with
high-density antibodies to target unique ligands in CRC [169].
Nowadays, exosomes are being studied as potential nano-carriers
therapy for a variety of disorders, including those affecting the central
nervous system (CNS), such as Parkinson's and Alzheimer's. Because of
their small size, exosomes can cross the blood–brain barrier allowing
drugs to enter the CNS through a systemic route of administration.
Exosomes can helpamyloid-peptide degradation, by acting as "waste
bags" in Alzheimer's disease allowing cells to get rid of proteins that are
no longer useful. In addition, they can also aid with cell differentiation
into neurons through their miRNA cargo, [170].
As previously mentioned, exosomes can act as naturally-equipped
vehicles/carriers for a wide-array of molecules and genetic materials
[171] to effectively silence oncogenes overexpressed in many tumours
[172]. All of this nominates exosomes as promising nano-bio-materials in
modern advanced drug delivery systems.
Tumor-associated-antigens (TAAs), which are antigen molecules
found on tumour cells and healthy cells, can be synthesised in trace
quantities by healthy cells, but are highly expressed on cancer cells

2.7. Exosomal-LncRNAs future perspectives in CRC diagnosis and
treatment
In order to use exosomal lncRNAs as new innovative biomarkers for
CRC, they must be isolated and detected with high purity and accuracy
as well. Currently, various methods have been created, each with its own
set of benefits and drawbacks that must be weighed. The proper
approach should be chosen in context in accordance with the study's
aims [184]. Exosomal lncRNAs from biofluids must be prepared using
defined processes before being used in diagnosis and/or tratment. Many
pre-analytical parameters, such as the time of fluid collection, fluid
preservation, and RNA separation methodology, among others, have an
impact on RNA abundance levels in body fluids both inside and outside
EVs [185]. Thus, despite certain hurdles in the clinical application of
exosomes, severalunique features of these EVs suggest that they can
indeed provide noveldiagnostic/prognostic biomarkers for CRC [143].
Hopefully, future research and efforts will unveil the best method and
practice to isolate and assess these exosomes and their cargos.
On the other hand, exosomes have been demonstrated to have
unique features, such as the ability to deliver antigens, making them
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Fig. 3. Faces of exosomes and its LncRNAs Cargo in CRC; A) the Evil, B) the Goodness; CRC: colorectal cancer; mets: metastasis.

potentially smart vehicles for cancer immunotherapy [186]. Also,
several reports have suggested that loading chemotherapeutic medicines
into exosomes is one of the most successful ways for exosome-based
cancer therapy, particularly for targeting cancer stem cells in vivo.
Furthermore, in animal tumor models, chemotherapeutic medication
delivery by exosomes has stronger anticancer effects than free medicines
[187]. For example in a colon adenocarcinoma mouse model, exosomedelivered doxorubicin reduced tumour growth significantly more
effectively than free orliposome-delivered doxorubicin [188]. To date,
studies have used viral and nonviral approaches to engineer parent cells
to release modified exosomes (endogenous loading), or to manipulate
exosome content directly after secretion (exogenous loading). While the
majority of studies have focused on exosome content engineering, there
is growing interest in techniques to alter the exosome surface to allow
targeted uptake by tumour cells while sparing healthy cells. Accord
ingly, the possibility to engineer exosomal content/surface and migra
tory patterns has a lot of promise.However, further in-depth elucidation
in the future for the various mechanisms which control exosomal cargo
packaging, release, and uptake by target cells is critical to the successful
translation of this promising approach to the clinical setting [189].
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3. Conclusion

Appendix A. Supplementary data

Exosomes, as small extracellular nano-sized vesicles, are carrying
essential cargos, mRNAs, miRNAs, lncRNAs, siRNAs and proteins,
related to the TME. These NVs, via their cargos, play a variety of func
tional key roles in CRC-related hallmarks as tumor cell growth, cancer
initiation, cell signalling, cancer progression as well as cancer cells
migration and/or metastasis, epigenetic modulation and drugresistance. Exosomes represent promising bio-inspired nano-sized par
ticles for cancer diagnosis/prognosis as well as for treatment delivery.

Supplementary data to this article can be found online at https://doi.
org/10.1016/j.lfs.2022.120325.
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E. Van Der Pol, A. N. Böing, P. Harrison, A. Sturk, et al., Classification, Functions,
and Clinical Relevance of Extracellular Vesicles. Pharmacological Reviews, vol.
64, no.3: pp. 676–705 DOI: 10.1124/pr.112.005983.2012.
D. Ha, N. Yang, and V. Nadithe, Exosomes as therapeutic drug carriers and
delivery vehicles across biological membranes: current perspectives and future
challenges. Acta Pharmaceutica Sinica B, vol. 6, no.4: pp. 287–296 DOI: 10.1016/
j.apsb.2016.02.001.2016.
J. L. Hood, Post isolation modification of exosomes for nanomedicine
applications. Nanomedicine, vol. 11, no.13: pp. 1745–1756 DOI.2016.
N. Bastos, C. F. Ruivo, S. Da Silva, and S. A. Melo, Exosomes in cancer: Use them
or target them? Seminars in Cell & Developmental Biology, vol. 78: pp. 13–21
DOI: 10.1016/j.semcdb.2017.08.009.2018.
A. Srivastava, N. Amreddy, A. Babu, J. Panneerselvam, et al., Nanosomes carrying
doxorubicin exhibit potent anticancer activity against human lung cancer cells.
Scientific Reports, vol. 6, no.1 DOI: 10.1038/srep38541.2016.
Y. Li, Y. Gao, C. Gong, Z. Wang, et al., A33 antibody-functionalized exosomes for
targeted delivery of doxorubicin against colorectal cancer. Nanomedicine:
Nanotechnology, Biology and Medicine, vol. 14, no.7: pp. 1973–1985 DOI:
10.1016/j.nano.2018.05.020.2018.
D. Rufino-Ramos, P. R. Albuquerque, V. Carmona, R. Perfeito, et al., Extracellular
vesicles: Novel promising delivery systems for therapy of brain diseases. Journal
of Controlled Release, vol. 262: pp. 247–258 DOI: 10.1016/j.
jconrel.2017.07.001.2017.

15

